+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diarrhea - Pipeline Review, H2 2020

  • ID: 5137299
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 156 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Cosmo Pharmaceuticals NV
  • Immuron Ltd
  • Napo Pharmaceuticals Inc
  • Orphomed Inc
  • RaQualia Pharma Inc
  • MORE
Diarrhea - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2020, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 2, 15 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Cosmo Pharmaceuticals NV
  • Immuron Ltd
  • Napo Pharmaceuticals Inc
  • Orphomed Inc
  • RaQualia Pharma Inc
  • MORE
  • Introduction
  • Diarrhea - Overview
  • Diarrhea - Therapeutics Development
  • Diarrhea - Therapeutics Assessment
  • Diarrhea - Companies Involved in Therapeutics Development
  • Diarrhea - Drug Profiles
  • Diarrhea - Dormant Projects
  • Diarrhea - Discontinued Products
  • Diarrhea - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Diarrhea, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Diarrhea - Pipeline by Albireo Pharma Inc, H2 2020
  • Diarrhea - Pipeline by Allergan Ltd, H2 2020
  • Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2020
  • Diarrhea - Pipeline by Boston Pharmaceuticals Inc, H2 2020
  • Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
  • Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2020
  • Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2020
  • Diarrhea - Pipeline by Glycosyn LLC, H2 2020
  • Diarrhea - Pipeline by Hilleman Laboratories Pvt Ltd, H2 2020
  • Diarrhea - Pipeline by Immuron Ltd, H2 2020
  • Diarrhea - Pipeline by Kaleido Biosciences Inc, H2 2020
  • Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2020
  • Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2020
  • Diarrhea - Pipeline by MyBiotics Pharma Ltd, H2 2020
  • Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2020
  • Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2020
  • Diarrhea - Pipeline by Novartis AG, H2 2020
  • Diarrhea - Pipeline by OnQuality Pharmaceutical USA LLC, H2 2020
  • Diarrhea - Pipeline by Orphomed Inc, H2 2020
  • Diarrhea - Pipeline by Pharmascience Inc, H2 2020
  • Diarrhea - Pipeline by Prokarium Ltd, H2 2020
  • Diarrhea - Pipeline by Protagonist Therapeutics Inc, H2 2020
  • Diarrhea - Pipeline by RaQualia Pharma Inc, H2 2020
  • Diarrhea - Pipeline by Rebiotix Inc, H2 2020
  • Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2020
  • Diarrhea - Pipeline by RxBio Inc, H2 2020
  • Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2020
  • Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2020
  • Diarrhea - Pipeline by Syntiron LLC, H2 2020
  • Diarrhea - Pipeline by Yisheng Biopharma Co Ltd, H2 2020
  • Diarrhea - Pipeline by Zhiyi Pharmaceuticals Inc, H2 2020
  • Diarrhea - Dormant Projects, H2 2020
  • Diarrhea - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Diarrhea - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Diarrhea - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Diarrhea, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Albireo Pharma Inc
  • Allergan Ltd
  • AzurRx BioPharma Inc
  • Boston Pharmaceuticals Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • Cosmo Pharmaceuticals NV
  • DiscoveryBiomed Inc
  • Glycosyn LLC
  • Hilleman Laboratories Pvt Ltd
  • Immuron Ltd
  • Kaleido Biosciences Inc
  • Kuhnil Pharmaceutical Co Ltd
  • Miyarisan Pharmaceutical Company Ltd
  • MyBiotics Pharma Ltd
  • Napo Pharmaceuticals Inc
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • OnQuality Pharmaceutical USA LLC
  • Orphomed Inc
  • Pharmascience Inc
  • Prokarium Ltd
  • Protagonist Therapeutics Inc
  • RaQualia Pharma Inc
  • Rebiotix Inc
  • RedHill Biopharma Ltd
  • RxBio Inc
  • Scandinavian Biopharma Holding AB
  • Synthetic Biologics Inc
  • Syntiron LLC
  • Yisheng Biopharma Co Ltd
  • Zhiyi Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll